{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:10Z","timestamp":1786982770300,"version":"build-2736575974"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T00:00:00Z","timestamp":1683504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs R D"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1007\/s40268-023-00422-w","type":"journal-article","created":{"date-parts":[[2023,5,8]],"date-time":"2023-05-08T06:02:38Z","timestamp":1683525758000},"page":"155-163","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Single-Centre Real-World Study on Drug Survival and Effectiveness of Brodalumab for Treatment of Psoriasis and Psoriatic Arthritis"],"prefix":"10.1007","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1965-4242","authenticated-orcid":false,"given":"Cathrine Dawn B\u00fcttner","family":"Elgaard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1816-4508","authenticated-orcid":false,"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6082-5096","authenticated-orcid":false,"given":"Kasper Fjellhaugen","family":"Hjuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,5,8]]},"reference":[{"issue":"4","key":"422_CR1","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1046\/j.1365-2230.2001.00832.x","volume":"26","author":"E Christophers","year":"2001","unstructured":"Christophers E. Psoriasis\u2014epidemiology and clinical spectrum. Clin Exp Dermatol. 2001;26(4):314\u201320.","journal-title":"Clin Exp Dermatol"},{"issue":"1","key":"422_CR2","first-page":"18","volume":"99","author":"K Danielsen","year":"2019","unstructured":"Danielsen K, Duvetorp A, Iversen L, et\u00a0al. Prevalence of psoriasis and psoriatic arthritis and patient perceptions of severity in Sweden, Norway and Denmark: results from the Nordic Patient Survey of Psoriasis and Psoriatic Arthritis. Acta Derm Venereol. 2019;99(1):18\u201325.","journal-title":"Acta Derm Venereol"},{"issue":"2","key":"422_CR3","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/jid.2012.339","volume":"133","author":"R Parisi","year":"2013","unstructured":"Parisi R, Symmons DP, Griffiths CE, et\u00a0al. Global epidemiology of psoriasis: a systematic review of incidence and prevalence. J Invest Dermatol. 2013;133(2):377\u201385.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"422_CR4","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1097\/BOR.0000000000000147","volume":"27","author":"PJ Mease","year":"2015","unstructured":"Mease PJ. Inhibition of interleukin-17, interleukin-23 and the TH17 cell pathway in the treatment of psoriatic arthritis and psoriasis. Curr Opin Rheumatol. 2015;27(2):127\u201333.","journal-title":"Curr Opin Rheumatol"},{"issue":"3","key":"422_CR5","doi-asserted-by":"crossref","first-page":"e13403","DOI":"10.1111\/dth.13403","volume":"33","author":"P Facheris","year":"2020","unstructured":"Facheris P, Valenti M, Pavia G, et\u00a0al. Brodalumab: a new way to inhibit IL-17 in psoriasis. Dermatol Ther. 2020;33(3):e13403.","journal-title":"Dermatol Ther"},{"issue":"8","key":"422_CR6","doi-asserted-by":"crossref","first-page":"3828","DOI":"10.4049\/jimmunol.1301737","volume":"192","author":"CB Russell","year":"2014","unstructured":"Russell CB, Rand H, Bigler J, et\u00a0al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol. 2014;192(8):3828\u201336.","journal-title":"J Immunol"},{"key":"422_CR7","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2147\/CCID.S67534","volume":"7","author":"AS L\u00f8nnberg","year":"2014","unstructured":"L\u00f8nnberg AS, Zachariae C, Skov L. Targeting of interleukin-17 in the treatment of psoriasis. Clin Cosmet Investig Dermatol. 2014;7:251\u20139.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"422_CR8","first-page":"1","volume":"29","author":"M Kojanova","year":"2022","unstructured":"Kojanova M, Hugo J, Velackova B, et\u00a0al. Efficacy, safety, and drug survival of patients with psoriasis treated with IL-17 inhibitors\u2014brodalumab, ixekizumab, and secukinumab: real-world data from the Czech Republic BIOREP registry. J Dermatolog Treat. 2022;29:1\u201311.","journal-title":"J Dermatolog Treat"},{"issue":"9","key":"422_CR9","first-page":"e15667","volume":"35","author":"M Megna","year":"2022","unstructured":"Megna M, Potestio L, Camela E, et\u00a0al. Ixekizumab and brodalumab indirect comparison in the treatment of moderate to severe psoriasis: results from an Italian single-center retrospective study in a real-life setting. Dermatol Ther. 2022;35(9):e15667.","journal-title":"Dermatol Ther"},{"issue":"6","key":"422_CR10","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1080\/09546634.2018.1427205","volume":"29","author":"L Sawyer","year":"2018","unstructured":"Sawyer L, Fotheringham I, Wright E, et\u00a0al. The comparative efficacy of brodalumab in patients with moderate-to-severe psoriasis: a systematic literature review and network meta-analysis. J Dermatolog Treat. 2018;29(6):557\u201368.","journal-title":"J Dermatolog Treat"},{"issue":"2","key":"422_CR11","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1111\/jdv.15277","volume":"33","author":"LM Sawyer","year":"2019","unstructured":"Sawyer LM, Cornic L, Levin L, et\u00a0al. Long-term efficacy of novel therapies in moderate-to-severe plaque psoriasis: a systematic review and network meta-analysis of PASI response. J Eur Acad Dermatol Venereol. 2019;33(2):355\u201366.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"422_CR12","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1111\/jcpt.13153","volume":"45","author":"R D\u00edaz Acedo","year":"2020","unstructured":"D\u00edaz Acedo R, Galvan Banqueri M, M\u00e1rquez SE. Indirect comparison of anti-interleukin 17 targeted biological treatments for moderate-to-severe psoriasis. J Clin Pharm Ther. 2020;45(4):715\u201321.","journal-title":"J Clin Pharm Ther"},{"issue":"2","key":"422_CR13","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1016\/j.jaad.2017.03.026","volume":"77","author":"A Blauvelt","year":"2017","unstructured":"Blauvelt A, Papp KA, Lebwohl MG, et\u00a0al. Rapid onset of action in patients with moderate-to-severe psoriasis treated with brodalumab: a pooled analysis of data from two phase 3 randomized clinical trials (AMAGINE-2 and AMAGINE-3). J Am Acad Dermatol. 2017;77(2):372\u20134.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"422_CR14","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/jdv.15920","volume":"34","author":"A Egeberg","year":"2020","unstructured":"Egeberg A, Andersen YMF, Halling-Overgaard AS, et\u00a0al. Systematic review on rapidity of onset of action for interleukin-17 and interleukin-23 inhibitors for psoriasis. J Eur Acad Dermatol Venereol. 2020;34(1):39\u201346.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"14","key":"422_CR15","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1056\/NEJMoa1503824","volume":"373","author":"M Lebwohl","year":"2015","unstructured":"Lebwohl M, Strober B, Menter A, et\u00a0al. Phase 3 studies comparing brodalumab with ustekinumab in psoriasis. N Engl J Med. 2015;373(14):1318\u201328.","journal-title":"N Engl J Med"},{"issue":"2","key":"422_CR16","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1111\/bjd.14493","volume":"175","author":"KA Papp","year":"2016","unstructured":"Papp KA, Reich K, Paul C, et\u00a0al. A prospective phase III, randomized, double-blind, placebo-controlled study of brodalumab in patients with moderate-to-severe plaque psoriasis. Br J Dermatol. 2016;175(2):273\u201386.","journal-title":"Br J Dermatol"},{"issue":"5","key":"422_CR17","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1016\/j.jaad.2013.07.023","volume":"69","author":"PJ Mease","year":"2013","unstructured":"Mease PJ, Gladman DD, Papp KA, et\u00a0al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European\/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729\u201335.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"422_CR18","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1136\/annrheumdis-2019-216835","volume":"80","author":"PJ Mease","year":"2021","unstructured":"Mease PJ, Helliwell PS, Hjuler KF, et\u00a0al. Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trials. Ann Rheum Dis. 2021;80(2):185\u201393.","journal-title":"Ann Rheum Dis"},{"key":"422_CR19","unstructured":"Siliq Prescribing Information: U.S. Food and Drug Administration; 2017. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761032lbl.pdf. Accessed 8 August 2022."},{"key":"422_CR20","unstructured":"Kyntheum: EPAR-Product Information: European Medicines Agency; 2017. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/kyntheum-epar-product-information_en.pdf. Accessed 22 August 2022."},{"key":"422_CR21","unstructured":"LUMICEF\u00ae approved in Japan: Kyowa Kirin; 2016. https:\/\/www.kyowakirin.com\/media_center\/news_releases\/2016\/e20160704_01.html. Accessed August 2022."},{"key":"422_CR22","unstructured":"Medicinr\u00e5det. Medicinr\u00e5dets l\u00e6gemiddelrekommandation og behandlingsvejledning vedr\u00f8rende l\u00e6gemidler til moderat til sv\u00e6r plaque psoriasis. 2022 November."},{"issue":"4","key":"422_CR23","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M, et\u00a0al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol. 2008;61(4):344\u20139.","journal-title":"J Clin Epidemiol"},{"key":"422_CR24","first-page":"1","volume":"18","author":"CDB Elgaard","year":"2022","unstructured":"Elgaard CDB, Iversen L, Hjuler KF. Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis. J Dermatol Treat. 2022;18:1\u20139.","journal-title":"J Dermatol Treat"},{"key":"422_CR25","doi-asserted-by":"crossref","first-page":"509","DOI":"10.2147\/CCID.S211938","volume":"12","author":"A Pinter","year":"2019","unstructured":"Pinter A, Bonnekoh B, Hadshiew IM, et\u00a0al. Brodalumab for the treatment of moderate-to-severe psoriasis: case series and literature review. Clin Cosmet Investig Dermatol. 2019;12:509\u201317.","journal-title":"Clin Cosmet Investig Dermatol"},{"key":"422_CR26","unstructured":"Medicinr\u00e5det. Medicinr\u00e5dets l\u00e6gemiddelrekommandation og behandlingsvejledning vedr\u00f8rende l\u00e6gemidler til moderat til sv\u00e6r plaque psoriasis. 2020 October."},{"issue":"7","key":"422_CR27","doi-asserted-by":"crossref","first-page":"e15532","DOI":"10.1111\/dth.15532","volume":"35","author":"E Tampouratzi","year":"2022","unstructured":"Tampouratzi E, Papakonstantis M, Katsantonis J, et\u00a0al. Clinical evidence on the use of brodalumab for the treatment of psoriasis in Greece: experience from clinical practice of four tertiary hospitals. Dermatol Ther. 2022;35(7):e15532.","journal-title":"Dermatol Ther"},{"issue":"4","key":"422_CR28","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1111\/1346-8138.15247","volume":"47","author":"C Ohata","year":"2020","unstructured":"Ohata C, Ohyama B, Katayama E, et\u00a0al. Real-world efficacy and safety of interleukin-17 inhibitors for psoriasis: a single-center experience. J Dermatol. 2020;47(4):405\u20138.","journal-title":"J Dermatol"},{"issue":"1","key":"422_CR29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1111\/1346-8138.15146","volume":"47","author":"M Kishimoto","year":"2020","unstructured":"Kishimoto M, Komine M, Kamiya K, et\u00a0al. Drug survival of biologic agents for psoriatic patients in a real-world setting in Japan. J Dermatol. 2020;47(1):33\u201340.","journal-title":"J Dermatol"},{"issue":"4","key":"422_CR30","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40257-021-00598-4","volume":"22","author":"T Torres","year":"2021","unstructured":"Torres T, Puig L, Vender R, et\u00a0al. Drug survival of IL-12\/23, IL-17 and IL-23 inhibitors for psoriasis treatment: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2021;22(4):567\u201379.","journal-title":"Am J Clin Dermatol"},{"key":"422_CR31","first-page":"1","volume":"13","author":"P Dapavo","year":"2021","unstructured":"Dapavo P, Siliquini N, Mastorino L, et\u00a0al. Efficacy, safety, and drug survival of IL-23, IL-17, and TNF-alpha inhibitors for psoriasis treatment: a retrospective study. J Dermatol Treat. 2021;13:1\u20136.","journal-title":"J Dermatol Treat"},{"key":"422_CR32","first-page":"1","volume":"23","author":"E Papadavid","year":"2022","unstructured":"Papadavid E, Zafeiriou E, Georgiou S, et\u00a0al. Real-world clinical outcomes of treatment with brodalumab in patients with moderate-to-severe psoriasis: a retrospective, 24-month experience from four academic dermatology centers in Greece. J Dermatol Treat. 2022;23:1\u20137.","journal-title":"J Dermatol Treat"},{"issue":"6","key":"422_CR33","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1007\/s40257-022-00722-y","volume":"23","author":"T Torres","year":"2022","unstructured":"Torres T, Puig L, Vender R, et\u00a0al. Drug survival of interleukin (IL)-17 and IL-23 inhibitors for the treatment of psoriasis: a retrospective multi-country, multicentric cohort study. Am J Clin Dermatol. 2022;23(6):891\u2013904.","journal-title":"Am J Clin Dermatol"},{"issue":"3","key":"422_CR34","doi-asserted-by":"crossref","first-page":"786","DOI":"10.1111\/bjd.14888","volume":"176","author":"J Zweegers","year":"2017","unstructured":"Zweegers J, Roosenboom B, van de Kerkhof PC, et\u00a0al. Frequency and predictors of a high clinical response in patients with psoriasis on biological therapy in daily practice: results from the prospective, multicenter BioCAPTURE cohort. Br J Dermatol. 2017;176(3):786\u201393.","journal-title":"Br J Dermatol"},{"issue":"11","key":"422_CR35","doi-asserted-by":"crossref","first-page":"971","DOI":"10.2340\/00015555-3245","volume":"99","author":"L Puig","year":"2019","unstructured":"Puig L, Dossenbach M, Berggren L, et\u00a0al. Absolute and relative psoriasis area and severity indices (PASI) for comparison of the efficacy of ixekizumab to etanercept and placebo in patients with moderate-to-severe plaque psoriasis: an integrated analysis of UNCOVER-2 and UNCOVER-3 outcomes. Acta Derm Venereol. 2019;99(11):971\u20137.","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"422_CR36","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.jdermsci.2022.02.007","volume":"105","author":"S Imafuku","year":"2022","unstructured":"Imafuku S, Ohata C, Okubo Y, et\u00a0al. Effectiveness of brodalumab in achieving treatment satisfaction for patients with plaque psoriasis: the ProLOGUE study. J Dermatol Sci. 2022;105(3):176\u201384.","journal-title":"J Dermatol Sci"},{"issue":"9","key":"422_CR37","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1080\/14712598.2021.1941862","volume":"21","author":"M Galluzzo","year":"2021","unstructured":"Galluzzo M, Caldarola G, De Simone C, et\u00a0al. Use of brodalumab for the treatment of chronic plaque psoriasis: a one-year real-life study in the Lazio region, Italy. Expert Opin Biol Ther. 2021;21(9):1299\u2013310.","journal-title":"Expert Opin Biol Ther"},{"issue":"3","key":"422_CR38","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/jdv.16931","volume":"35","author":"MC Fargnoli","year":"2021","unstructured":"Fargnoli MC, Esposito M, Dapavo P, et\u00a0al. Brodalumab for the treatment of moderate-to-severe plaque-type psoriasis: a real-life, retrospective 24-week experience. J Eur Acad Dermatol Venereol. 2021;35(3):693\u2013700.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"8","key":"422_CR39","doi-asserted-by":"crossref","first-page":"3211","DOI":"10.1080\/09546634.2022.2125265","volume":"33","author":"L Mastorino","year":"2022","unstructured":"Mastorino L, Cariti C, Susca S, et\u00a0al. Brodalumab efficacy in bio-na\u00efve psoriasis patients: real-life experience of 202 subjects up to 48 weeks. J Dermatol Treat. 2022;33(8):3211\u20133.","journal-title":"J Dermatol Treat"},{"issue":"4","key":"422_CR40","first-page":"354","volume":"21","author":"M Lebwohl","year":"2022","unstructured":"Lebwohl M, Menter A, Lain E, et\u00a0al. Long-term skin clearance with brodalumab in patients with psoriasis and inadequate response to prior biologics. J Drugs Dermatol. 2022;21(4):354\u201370.","journal-title":"J Drugs Dermatol"},{"key":"422_CR41","doi-asserted-by":"crossref","unstructured":"Merola JF, Kavanaugh A, Lebwohl MG, et\u00a0al. Clinical efficacy and safety of psoriasis treatments in patients with concomitant metabolic syndrome: a narrative review. Dermatol Ther (Heidelb). 2022.","DOI":"10.1007\/s13555-022-00790-2"},{"issue":"10","key":"422_CR42","doi-asserted-by":"crossref","first-page":"adv00579","DOI":"10.2340\/actadv.v101.351","volume":"101","author":"CW Schwarz","year":"2021","unstructured":"Schwarz CW, Loft N, Rasmussen MK, et\u00a0al. Predictors of response to biologics in patients with moderate-to-severe psoriasis: a Danish Nationwide Cohort Study. Acta Derm Venereol. 2021;101(10):adv00579.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"422_CR43","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/bcpt.13202","volume":"125","author":"S Timmermann","year":"2019","unstructured":"Timmermann S, Hall A. Population pharmacokinetics of brodalumab in patients with moderate to severe plaque psoriasis. Basic Clin Pharmacol Toxicol. 2019;125(1):16\u201325.","journal-title":"Basic Clin Pharmacol Toxicol"},{"issue":"7","key":"422_CR44","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1001\/jamadermatol.2022.1863","volume":"158","author":"C Enevold","year":"2022","unstructured":"Enevold C, Loft N, Bregnh\u00f8j A, et\u00a0al. Circulating brodalumab levels and therapy outcomes in patients with psoriasis treated with brodalumab: a case series. JAMA Dermatol. 2022;158(7):762\u20139.","journal-title":"JAMA Dermatol"},{"issue":"3","key":"422_CR45","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1111\/1346-8138.15690","volume":"48","author":"Y Yamaguchi","year":"2021","unstructured":"Yamaguchi Y, Kanai Y, Kitabayashi H, et\u00a0al. Relationship between serum trough levels and efficacy of brodalumab from a post hoc exploratory analysis of a Japanese study in patients with plaque psoriasis. J Dermatol. 2021;48(3):324\u201333.","journal-title":"J Dermatol"},{"issue":"1","key":"422_CR46","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.jdermsci.2015.10.009","volume":"81","author":"H Nakagawa","year":"2016","unstructured":"Nakagawa H, Niiro H, Ootaki K. Brodalumab, a human anti-interleukin-17-receptor antibody in the treatment of Japanese patients with moderate-to-severe plaque psoriasis: efficacy and safety results from a phase II randomized controlled study. J Dermatol Sci. 2016;81(1):44\u201352.","journal-title":"J Dermatol Sci"},{"issue":"2","key":"422_CR47","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.jaad.2019.05.095","volume":"82","author":"L Puig","year":"2020","unstructured":"Puig L, Lebwohl M, Bachelez H, et\u00a0al. Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial. J Am Acad Dermatol. 2020;82(2):352\u20139.","journal-title":"J Am Acad Dermatol"},{"issue":"6","key":"422_CR48","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1111\/bjd.19132","volume":"183","author":"K Papp","year":"2020","unstructured":"Papp K, Menter A, Leonardi C, et\u00a0al. Long-term efficacy and safety of brodalumab in psoriasis through 120 weeks and after withdrawal and retreatment: subgroup analysis of a randomized phase III trial (AMAGINE-1). Br J Dermatol. 2020;183(6):1037\u201348.","journal-title":"Br J Dermatol"}],"container-title":["Drugs in R&D"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00422-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40268-023-00422-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40268-023-00422-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,6,26]],"date-time":"2023-06-26T12:36:27Z","timestamp":1687782987000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40268-023-00422-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,8]]},"references-count":48,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,6]]}},"alternative-id":["422"],"URL":"https:\/\/doi.org\/10.1007\/s40268-023-00422-w","relation":{},"ISSN":["1174-5886","1179-6901"],"issn-type":[{"value":"1174-5886","type":"print"},{"value":"1179-6901","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,5,8]]},"assertion":[{"value":"3 April 2023","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2023","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Cathrine Elgaard has received a personal scholarship from Novo Nordisk Foundation outside of the submitted work. Dr Iversen is employed by MC2 Therapeutics A\/S and has served as a consultant and\/or paid speaker for and\/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Astra Zeneca, BMS, Boehringer Ingelheim, Celgene, Centocor, Eli Lilly, Janssen Cilag, Kyowa, Leo Pharma, MSD, Novartis, Pfizer, Regranion, Samsung and Union Therapeutics UCB. Dr Hjuler has served as a consultant and advisor for the following companies: AbbVie, Bristol Myers Squibb (BMS), Janssen, LEO Pharma, UCB and Novartis, and has received speaking fees or grants from AbbVie, Eli Lilly, LEO Pharma, Novartis and Janssen.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}},{"value":"This project was reviewed and approved by the administration of Aarhus University Hospital. In Denmark, register studies require no approval from an ethics committee. The study complied with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable. In Denmark, register studies require no informed consent according to the Danish Health Care Act, \u00a7 42 d, section 2 (2022).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The datasets generated during the current study are available from the corresponding author on reasonable request.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"The dataset generated during the current study is available from the corresponding author on reasonable request.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship. Concept and design: KFH. Acquisition, analysis, or interpretation of data: CDBE, KFH. Drafting of the manuscript: CDBE. Critical revision of the manuscript for important intellectual content: CDBE, LI, KFH. Statistical analysis: CDBE. Administrative, technical, or material support: LI. Supervision: KFH. All authors read and approved the final manuscript.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}